Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding
Management of trauma patients with severe bleeding has led to criteria before considering use of recombinant activated factor VII (rFVIIa), including haemoglobin >8 g dl−1, serum fibrinogen ≥1.0 g l−1, platelets >50,000 × 109l−1, arterial pH ≥ 7.20, and body temperature ≥34 °C. We hypothesized...
Gespeichert in:
| Veröffentlicht in: | British journal of anaesthesia : BJA 2016-10, Vol.117 (4), p.470-476 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 476 |
|---|---|
| container_issue | 4 |
| container_start_page | 470 |
| container_title | British journal of anaesthesia : BJA |
| container_volume | 117 |
| creator | Payen, J.-F. Berthet, M Genty, C Declety, P Garrigue-Huet, D Morel, N Bouzat, P Riou, B Bosson, J.-L. |
| description | Management of trauma patients with severe bleeding has led to criteria before considering use of recombinant activated factor VII (rFVIIa), including haemoglobin >8 g dl−1, serum fibrinogen ≥1.0 g l−1, platelets >50,000 × 109l−1, arterial pH ≥ 7.20, and body temperature ≥34 °C. We hypothesized that meeting these criteria is associated with improved outcomes.
In this prospective cohort study of 26 French trauma centres, subjects were included if they received rFVIIa for persistent massive bleeding despite appropriate care after severe blunt and/or penetrating trauma.
After surgery and/or embolization as haemostatic interventions, 112 subjects received a first dose of 103 μg kg−1rFVIIa (82-200) (median, 25th-75thpercentile) at 420 min (285-647) post-trauma. Of these, 71 (63%) “responders” were still alive at 24h post-trauma and had their transfusion requirements reduced by > 2 packed red blood cell units after rFVIIa treatment. Mortality was 54% on day 30 post-trauma. There were 21%, 44% and 35% subjects who fulfilled 0-1, 2-3 or 4-5, respectively, of the guidelines before receiving rFVIIa. Survival at day 30 was 13%, 49% and 64% and the proportion of responders was 39%, 64% and 82%, when subjects fulfilled 0-1, 2-3 or 4-5 conditions, respectively (both P |
| doi_str_mv | 10.1093/bja/aew276 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1858105651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0007091217301678</els_id><sourcerecordid>1858105651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-46a7f4f28bc887fe512fc05c49ed9c318f5165e56f47e569bfd866180d63f69c3</originalsourceid><addsrcrecordid>eNptkd1KHDEYQENR6mp70weQXEphajIz-ZlLEdsuCIViexsyyRf7yfysSWaXfQjf2ciqV71JAjk58J0Q8oWzb5x1zWX_YC8t7GolP5AVbxWvpFL8iKwYY6piHa9PyGlKD4xxVXfiIzmpNVNKNO2KPP0GvzjwdJxjtgPmPe33dATION3T-wU9DDgBdREzRLS0hzBHoEt6uY_g5rHHyU6ZWpdxa3NRhXKcI_27XlOcaIItlAc52mW0dGMzwpQT3WH-R0ebEm6B9gOAL8JP5DjYIcHn1_2M_Pl-c3f9s7r99WN9fXVbuUbqXLXSqtCGWvdOaxVA8Do4Jlzbge9cw3UQXAoQMrSqrF0fvJaSa-ZlE2QhzsjFwbuJ8-MCKZsRk4NhsBPMSzJcC82ZkIIX9OsBdXFOKUIwm4ijjXvDmXnJb0p-c8hf4PNX79KP4N_Rt94FaA8AlOm2CNEkV3qUD8DSMhs_4_-8z0TklvU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1858105651</pqid></control><display><type>article</type><title>Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Payen, J.-F. ; Berthet, M ; Genty, C ; Declety, P ; Garrigue-Huet, D ; Morel, N ; Bouzat, P ; Riou, B ; Bosson, J.-L.</creator><creatorcontrib>Payen, J.-F. ; Berthet, M ; Genty, C ; Declety, P ; Garrigue-Huet, D ; Morel, N ; Bouzat, P ; Riou, B ; Bosson, J.-L. ; for the Novoseven Trauma investigators ; Novoseven Trauma investigators</creatorcontrib><description>Management of trauma patients with severe bleeding has led to criteria before considering use of recombinant activated factor VII (rFVIIa), including haemoglobin >8 g dl−1, serum fibrinogen ≥1.0 g l−1, platelets >50,000 × 109l−1, arterial pH ≥ 7.20, and body temperature ≥34 °C. We hypothesized that meeting these criteria is associated with improved outcomes.
In this prospective cohort study of 26 French trauma centres, subjects were included if they received rFVIIa for persistent massive bleeding despite appropriate care after severe blunt and/or penetrating trauma.
After surgery and/or embolization as haemostatic interventions, 112 subjects received a first dose of 103 μg kg−1rFVIIa (82-200) (median, 25th-75thpercentile) at 420 min (285-647) post-trauma. Of these, 71 (63%) “responders” were still alive at 24h post-trauma and had their transfusion requirements reduced by > 2 packed red blood cell units after rFVIIa treatment. Mortality was 54% on day 30 post-trauma. There were 21%, 44% and 35% subjects who fulfilled 0-1, 2-3 or 4-5, respectively, of the guidelines before receiving rFVIIa. Survival at day 30 was 13%, 49% and 64% and the proportion of responders was 39%, 64% and 82%, when subjects fulfilled 0-1, 2-3 or 4-5 conditions, respectively (both P<0.01).
In actively bleeding trauma patients, meeting guideline criteria before considering rFVIIa was associated with lower mortality and a higher proportion of responders to the rFVIIa.</description><identifier>ISSN: 0007-0912</identifier><identifier>EISSN: 1471-6771</identifier><identifier>DOI: 10.1093/bja/aew276</identifier><identifier>PMID: 28077534</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>factor VIIa ; haemorrhage ; shock, traumatic</subject><ispartof>British journal of anaesthesia : BJA, 2016-10, Vol.117 (4), p.470-476</ispartof><rights>2016 The Author(s)</rights><rights>The Author 2016. Published by Oxford University Press on behalf of the British Journal of Anaesthesia. All rights reserved. For Permissions, please email: journals.permissions@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-46a7f4f28bc887fe512fc05c49ed9c318f5165e56f47e569bfd866180d63f69c3</citedby><cites>FETCH-LOGICAL-c368t-46a7f4f28bc887fe512fc05c49ed9c318f5165e56f47e569bfd866180d63f69c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28077534$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Payen, J.-F.</creatorcontrib><creatorcontrib>Berthet, M</creatorcontrib><creatorcontrib>Genty, C</creatorcontrib><creatorcontrib>Declety, P</creatorcontrib><creatorcontrib>Garrigue-Huet, D</creatorcontrib><creatorcontrib>Morel, N</creatorcontrib><creatorcontrib>Bouzat, P</creatorcontrib><creatorcontrib>Riou, B</creatorcontrib><creatorcontrib>Bosson, J.-L.</creatorcontrib><creatorcontrib>for the Novoseven Trauma investigators</creatorcontrib><creatorcontrib>Novoseven Trauma investigators</creatorcontrib><title>Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding</title><title>British journal of anaesthesia : BJA</title><addtitle>Br J Anaesth</addtitle><description>Management of trauma patients with severe bleeding has led to criteria before considering use of recombinant activated factor VII (rFVIIa), including haemoglobin >8 g dl−1, serum fibrinogen ≥1.0 g l−1, platelets >50,000 × 109l−1, arterial pH ≥ 7.20, and body temperature ≥34 °C. We hypothesized that meeting these criteria is associated with improved outcomes.
In this prospective cohort study of 26 French trauma centres, subjects were included if they received rFVIIa for persistent massive bleeding despite appropriate care after severe blunt and/or penetrating trauma.
After surgery and/or embolization as haemostatic interventions, 112 subjects received a first dose of 103 μg kg−1rFVIIa (82-200) (median, 25th-75thpercentile) at 420 min (285-647) post-trauma. Of these, 71 (63%) “responders” were still alive at 24h post-trauma and had their transfusion requirements reduced by > 2 packed red blood cell units after rFVIIa treatment. Mortality was 54% on day 30 post-trauma. There were 21%, 44% and 35% subjects who fulfilled 0-1, 2-3 or 4-5, respectively, of the guidelines before receiving rFVIIa. Survival at day 30 was 13%, 49% and 64% and the proportion of responders was 39%, 64% and 82%, when subjects fulfilled 0-1, 2-3 or 4-5 conditions, respectively (both P<0.01).
In actively bleeding trauma patients, meeting guideline criteria before considering rFVIIa was associated with lower mortality and a higher proportion of responders to the rFVIIa.</description><subject>factor VIIa</subject><subject>haemorrhage</subject><subject>shock, traumatic</subject><issn>0007-0912</issn><issn>1471-6771</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNptkd1KHDEYQENR6mp70weQXEphajIz-ZlLEdsuCIViexsyyRf7yfysSWaXfQjf2ciqV71JAjk58J0Q8oWzb5x1zWX_YC8t7GolP5AVbxWvpFL8iKwYY6piHa9PyGlKD4xxVXfiIzmpNVNKNO2KPP0GvzjwdJxjtgPmPe33dATION3T-wU9DDgBdREzRLS0hzBHoEt6uY_g5rHHyU6ZWpdxa3NRhXKcI_27XlOcaIItlAc52mW0dGMzwpQT3WH-R0ebEm6B9gOAL8JP5DjYIcHn1_2M_Pl-c3f9s7r99WN9fXVbuUbqXLXSqtCGWvdOaxVA8Do4Jlzbge9cw3UQXAoQMrSqrF0fvJaSa-ZlE2QhzsjFwbuJ8-MCKZsRk4NhsBPMSzJcC82ZkIIX9OsBdXFOKUIwm4ijjXvDmXnJb0p-c8hf4PNX79KP4N_Rt94FaA8AlOm2CNEkV3qUD8DSMhs_4_-8z0TklvU</recordid><startdate>201610</startdate><enddate>201610</enddate><creator>Payen, J.-F.</creator><creator>Berthet, M</creator><creator>Genty, C</creator><creator>Declety, P</creator><creator>Garrigue-Huet, D</creator><creator>Morel, N</creator><creator>Bouzat, P</creator><creator>Riou, B</creator><creator>Bosson, J.-L.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201610</creationdate><title>Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding</title><author>Payen, J.-F. ; Berthet, M ; Genty, C ; Declety, P ; Garrigue-Huet, D ; Morel, N ; Bouzat, P ; Riou, B ; Bosson, J.-L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-46a7f4f28bc887fe512fc05c49ed9c318f5165e56f47e569bfd866180d63f69c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>factor VIIa</topic><topic>haemorrhage</topic><topic>shock, traumatic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Payen, J.-F.</creatorcontrib><creatorcontrib>Berthet, M</creatorcontrib><creatorcontrib>Genty, C</creatorcontrib><creatorcontrib>Declety, P</creatorcontrib><creatorcontrib>Garrigue-Huet, D</creatorcontrib><creatorcontrib>Morel, N</creatorcontrib><creatorcontrib>Bouzat, P</creatorcontrib><creatorcontrib>Riou, B</creatorcontrib><creatorcontrib>Bosson, J.-L.</creatorcontrib><creatorcontrib>for the Novoseven Trauma investigators</creatorcontrib><creatorcontrib>Novoseven Trauma investigators</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of anaesthesia : BJA</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Payen, J.-F.</au><au>Berthet, M</au><au>Genty, C</au><au>Declety, P</au><au>Garrigue-Huet, D</au><au>Morel, N</au><au>Bouzat, P</au><au>Riou, B</au><au>Bosson, J.-L.</au><aucorp>for the Novoseven Trauma investigators</aucorp><aucorp>Novoseven Trauma investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding</atitle><jtitle>British journal of anaesthesia : BJA</jtitle><addtitle>Br J Anaesth</addtitle><date>2016-10</date><risdate>2016</risdate><volume>117</volume><issue>4</issue><spage>470</spage><epage>476</epage><pages>470-476</pages><issn>0007-0912</issn><eissn>1471-6771</eissn><abstract>Management of trauma patients with severe bleeding has led to criteria before considering use of recombinant activated factor VII (rFVIIa), including haemoglobin >8 g dl−1, serum fibrinogen ≥1.0 g l−1, platelets >50,000 × 109l−1, arterial pH ≥ 7.20, and body temperature ≥34 °C. We hypothesized that meeting these criteria is associated with improved outcomes.
In this prospective cohort study of 26 French trauma centres, subjects were included if they received rFVIIa for persistent massive bleeding despite appropriate care after severe blunt and/or penetrating trauma.
After surgery and/or embolization as haemostatic interventions, 112 subjects received a first dose of 103 μg kg−1rFVIIa (82-200) (median, 25th-75thpercentile) at 420 min (285-647) post-trauma. Of these, 71 (63%) “responders” were still alive at 24h post-trauma and had their transfusion requirements reduced by > 2 packed red blood cell units after rFVIIa treatment. Mortality was 54% on day 30 post-trauma. There were 21%, 44% and 35% subjects who fulfilled 0-1, 2-3 or 4-5, respectively, of the guidelines before receiving rFVIIa. Survival at day 30 was 13%, 49% and 64% and the proportion of responders was 39%, 64% and 82%, when subjects fulfilled 0-1, 2-3 or 4-5 conditions, respectively (both P<0.01).
In actively bleeding trauma patients, meeting guideline criteria before considering rFVIIa was associated with lower mortality and a higher proportion of responders to the rFVIIa.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>28077534</pmid><doi>10.1093/bja/aew276</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0912 |
| ispartof | British journal of anaesthesia : BJA, 2016-10, Vol.117 (4), p.470-476 |
| issn | 0007-0912 1471-6771 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1858105651 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | factor VIIa haemorrhage shock, traumatic |
| title | Reduced mortality by meeting guideline criteria before using recombinant activated factor VII in severe trauma patients with massive bleeding |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T09%3A50%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20mortality%20by%20meeting%20guideline%20criteria%20before%20using%20recombinant%20activated%20factor%20VII%20in%20severe%20trauma%20patients%20with%20massive%20bleeding&rft.jtitle=British%20journal%20of%20anaesthesia%20:%20BJA&rft.au=Payen,%20J.-F.&rft.aucorp=for%20the%20Novoseven%20Trauma%20investigators&rft.date=2016-10&rft.volume=117&rft.issue=4&rft.spage=470&rft.epage=476&rft.pages=470-476&rft.issn=0007-0912&rft.eissn=1471-6771&rft_id=info:doi/10.1093/bja/aew276&rft_dat=%3Cproquest_cross%3E1858105651%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1858105651&rft_id=info:pmid/28077534&rft_els_id=S0007091217301678&rfr_iscdi=true |